Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer-Reference-Cited by-同舟云学术

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

Published:2008-09 Issue:2 Volume:6 Page:97-102
ISSN:1558-7673
Container-title:Clinical Genitourinary Cancer
language:en
Short-container-title:Clinical Genitourinary Cancer

Author:

Amato Robert J.,Jac Jaroslaw,Mohammad Taqi,Saxena Somya

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference26 articles.

1. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone;Rosenberg;Cancer,2007

2. Phase III trial of satraplatin, an oral platinum plus prednisone vs, prednisone alone in patients with hormone-refractory prostate cancer;Sternberg;Oncology,2005

3. Randomized phase II study of two doses of gefitinib in hormone refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group;Canil;J Clin Oncol,2005

4. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer;Small;J Clin Oncol,2006

5. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage;McMenamin;Cancer Res,1999

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials;Signal Transduction and Targeted Therapy;2022-06-24

2. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer;International Journal of Molecular Sciences;2021-10-14

3. Selective obstruction of the mTORC2 complex by a naturally occurring cholestane saponin (OSW-1) for inhibiting prostate cancer cell growth;Journal of Asian Natural Products Research;2021-07-22

4. The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer;Cells;2020-10-22

5. Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51;Biochemistry and Biophysics Reports;2020-09